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ABSTRACT
MicroRNAs are small non-coding RNAs that
modulate gene expression at post-transcriptional
level, playing a crucial role in cell differentiation
and development. Recently, some reports have
shown that a limited number of mammalian
microRNAs are also involved in anti-viral defense.
In this study, the analysis of the hepatitis B virus
(HBV) genome by the computer program MiRanda
led to the identification of seven sites that are po-
tential targets for human liver microRNAs. These
sites were found to be clustered in a 995-bp
segment within the viral polymerase ORF and the
overlapping surface antigen ORF, and conserved
among the most common HBV subtypes. The HBV
genomic targets were then subjected to a validation
test based on cultured hepatic cells (HepG2, HuH-7
and PLC/PRF/5) and luciferase reporter genes. In
this test, one of the selected microRNAs, hsa-
miR-125a-5p, was found to interact with the viral
sequence and to suppress the reporter activity
markedly. The microRNA was then shown to inter-
fere with the viral translation, down-regulating the
expression of the surface antigen. Overall, these
results support the emerging concept that some
mammalian microRNAs play a role in virus-host
interaction. Furthermore, they provide the basis for
the development of new strategies for anti-HBV
intervention.
INTRODUCTION
MicroRNAs (miRNAs) are small non-coding RNAs that
modulate gene expression at post-transcriptional level by
targeting mRNAs for degradation or by inhibiting trans-
lation (1). At the time of writing, the miRNA database
(http://www.mirbase.org) (2) contained  1100 human
miRNAs which may regulate up to 30% of the
protein-coding genes (3). MicroRNAs have been shown
to play a prevalent role in development and cell differen-
tiation, maintenance of stem cell character, and apoptosis
(4,5). Moreover, several studies indicate that miRNA
genes may act as oncogenes or tumor suppressors (6,7).
MicroRNAs are generally transcribed by RNA poly-
merase II as long precursors, pri-miRNAs, which are pro-
cessed in the nucleus to  70-nt hairpin structures by the
enzyme Drosha. These products, pre-miRNAs, are then
transported to the cytoplasm and processed into  22nt
mature miRNAs by the action of the multi-domain RNase
III-like enzyme Dicer (8). Each miRNA duplex is then
unwound and the strand with the lower stability in the
50-end (guide strand) is preferentially selected (9) and
incorporated into a large, dynamic multi-protein
complex called RNA-induced silencing complex (RISC).
The targets of miRNA-loaded RISC are mRNAs present-
ing a near-perfect sequence complementarity with 2–8nt
in the 50-portion of the miRNA (the so-called seed region),
and additional base pairings with its 30-region. RISC
mediates down-regulation of target gene expression by
cleavage or translational inhibition of the target mRNA.
The choice between these two modes of action is dictated
by the degree of complementarity between miRNA and its
target. Near-perfect complementarity produces cleavage
of the mRNA, followed by its complete degradation,
whereas partial complementarity causes translational in-
hibition (10). In vertebrates, most of the time, the conse-
quence is an inhibition of translation. In addition to
repressing translation, miRNA interactions can lead to
deadenylation and decapping, leading to rapid mRNA
decay (11).
RNA-mediated post-transcriptional gene silencing can
also be triggered by exogenous dsRNA molecules. In
plants and invertebrates, viral dsRNA molecules are pro-
cessed into small interfering RNAs (siRNAs) by Dicer and
are incorporated into RISC to target pathogen’s genome
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plants and invertebrates, a defensive role for RNA
silencing in vertebrates has not been sufﬁciently deﬁned.
In vertebrates, cell exposure to long dsRNA triggers the
interferon response as primary form of innate antiviral
defense. This leads to a global shutdown in protein trans-
lation, cellular RNA degradation and often the death of
virus-infected cells (14). Nevertheless, recent data provide
increasing evidence that vertebrate miRNAs may directly
affect viral gene expression.
In 2005, Voinnet and collaborators for the ﬁrst time
demonstrated that a mammalian miRNA, miR-32, has
an antiviral role (15). MiR-32 was shown to target the
open reading frame 2 of the primate foamy virus type 1
(PFV-1), thereby inhibiting viral mRNA translation and
restricting the accumulation of the retrovirus in cultured
human cells. Other cellular miRNAs, miR-196 and
miR-448, were found to be up-regulated by interferon
beta and capable of inhibiting hepatitis C virus (HCV)
replication (16). MicroRNAs miR-24 and miR-93 have
been shown to target vesicular stomatitis virus (VSV)
and protect mice against VSV infection (17). Interactions
between cellular miRNAs and human immunodeﬁciency
virus (HIV) also exist. One study has shown that miR-28,
miR-125b, miR-150, miR-223 and miR-382 are
overexpressed in resting T4 lymphocytes and are able to
target sequences in the 30-end of HIV-1 RNA, thus
silencing almost all viral messengers (18). Neutralizing
these cellular miRNAs in T4 cells from patients with
HIV under highly active antiretroviral therapy increased
by 10-fold the in vitro efﬁciency of virus isolation. These
observations strongly argue for a role of these cellular
miRNAs in HIV latency. Very recently, miR-125b has
been shown to affect the replication of human
papillomavirus (19). A database of computationally pre-
dicted viral targets for mammalian miRNAs has also been
established (20). Overall, these data indicate that some
cellular miRNAs are a part of the host’s innate antiviral
defense (21). However, it has also been proposed
that miRNAs are among the host molecules that viruses
co-opt to suppress their own replication to evade immune
elimination and establish a persistent infection (22).
In this study, we focused our interest on human hepa-
titis B virus (HBV), a widely spread hepatotropic virus
that causes persistent infections (23). We ﬁrst performed
an in silico analysis of the HBV genome looking for po-
tential target sites for human miRNAs, then these targets
were validated by assay methods based on cultured
hepatic cells. This work led to the identiﬁcation of
hsa-miR-125a-5p as an effective suppressor of the expres-
sion of HBV surface antigen.
MATERIALS AND METHODS
Materials
MiRIDIAN miR-125a-5p mimic, miRIDIAN miR-125a-
5p hairpin inhibitor, and their controls with unrelated se-
quences were from Dharmacon. DNA oligonucleotides
were obtained from Invitrogen. The psiCheck-2 vector
was purchased from Promega.
Computational analyses
Computer program miRanda (24) was used to scan the
genomes of HBV subtypes ayw, adw and adr (GeneBank
accession numbers X65257.1, X02763.1, AY123041.1, re-
spectively) for the presence of target sites for the human
miRNAs listed in miRBase (http://www.mirbase.org/) (2).
Search was conducted with the following cut-off param-
eters: minimal free energy of binding less than  12kcal/
mol and miRanda score >140. Alignment of the DNA
sequences of the viral genomes was performed with
ClustalW.
DNA constructs
The HBV genomic segments that were supposed to be
targeted by human miRNAs, whose size ranged from
18 to 29bp, were obtained by chemical synthesis of com-
plementary oligonucleotides containing upstream
XhoI and EcoRV restriction sites and a downstream
NotI site. Each couple of oligonucleotides was annealed,
50-phosphorylated with T4 polynucleotide kinase, and
ligated into XhoI and NotI sites of psiCheck-2.
Screening of recombinant clones was performed by diges-
tion with EcoRV. Selected constructs were then sequenced
to conﬁrm their identity. Control plasmids with inverted
or mutated sequences were obtained by the same
approach.
Cell cultures and transfections
Human hepatoblastoma HepG2 cells were cultured in
RPMI 1640 containing 10% fetal bovine serum, 2mM
L-glutamine, 50U/ml penicillin and 100mg/ml strepto-
mycin; cell line HuH-7 was cultured in DMEM containing
10% fetal bovine serum, 2mM L-glutamine and the same
antibiotics; PLC/PRF/5 cells were cultured as HuH-7
except that medium contained 0.1mM non-essential
amino acid. The day before transfection, cells were
trypsinized and seeded in medium without antibiotics in
12-well plates. Transfections were performed with cells at
80–90% of conﬂuence by using 3ml of Lipofectamine 2000
(Invitrogen) for 1mg of nucleic acids, as described by the
manufacturer. HepG2, HuH-7 and PLC/PRF/5 were
transfected with 0.2, 0.05 and 0.1mg of reporter plasmid,
respectively. After 6h, transfection mix was replaced with
complete medium.
Assays
Assays were performed 48h after transfection. Luciferase
assays were performed using the Dual-Luciferase
Reporter Assay System (Promega), as described (25).
Brieﬂy, cells were washed with phosphate buffered saline
and lysed chemically. Lysates were then centrifuged to
remove cellular debris and 20ml of the supernatants were
loaded into an automated luminometer (Turner
Biosystems). Then the instrument performed a sequential
auto-injection of 100ml of Luciferase Assay Reagent II
(substrate for ﬁreﬂy luciferase) and 100ml of Stop and
Glow Reagent (stop solution for ﬁreﬂy luciferase contain-
ing the substrate for Renilla luciferase). The mean of the
luciferase activities measured for 10s each were used to
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extracellular HBV surface antigen (HBsAg) produced by
PLC/PRF/5 cells was quantitated by an enzyme-linked
immunosorbent assay (Alpha Diagnostic International)
according to the manufacturer’s protocol. Each experi-
ment of transfection and subsequent assays was per-
formed at least three times. Reported data are the
mean±SD and statistical signiﬁcance was assessed with
Student’s t-test. Surface antigen mRNA was quantitated
by RT–PCR with primers binding upstream (50-TCCTCT
GGGATTCTTTCCCGA-30) and downstream (50-CACT
GCATGGCCTGAGGATG-30) of the target site for
hsa-miR125a-5p. Hsa-miR-125a-5p was quantitated by
RT-PCR using the TaqMan miRNA assays kit from
Applied Biosystems, as described (26).
RESULTS AND DISCUSSION
Prediction of target sites for human microRNAs
within HBV genome
HBV is characterized by a circular DNA genome of 3.2kb
which is only partially double-stranded (27). This is
replicated through an RNA intermediate, the pregenomic
RNA, which is produced by transcription of the viral
DNA by cellular RNA polymerase. Pregenomic RNA is
then converted into the viral DNA genome by the HBV
polymerase, a multifunctional enzyme with reverse tran-
scriptase, DNA-dependent DNA polymerase and RNase
H activities (28).
The computational analysis was performed with the
computer program miRanda, scanning plus strands of
the genomes of the most common HBV subtypes (ayw,
adw and adr) for the presence of target sites for human
miRNAs. Restriction of the results to (i) those targets that
are conserved in the three HBV subtypes, (ii) those
miRNA–mRNA pairings with a perfect matching of the
seed region (2–8nt of miRNA), and (iii) those microRNAs
that are known to be expressed in liver, the natural site of
infection, or in cultured hepatic cells (7,30), yielded seven
promising target sites. They were found to be clustered in
a 995-bp segment within the viral polymerase (P) ORF
and the overlapping surface antigen (S) ORF, as detailed
in Figure 1. The results of this search suggested that
human hepatic cells may use these miRNAs to down-
regulate the expression of HBV P and S genes.
Testing of HBV genomic targets for responsiveness to
human hepatic miRNAs
The most common methods for miRNA target validation
are based on reporter gene constructs transfected in
cultured mammalian cells (29). The seven HBV genomic
segments containing putative target sites for human
miRNAs were separately cloned downstream of the
Renilla luciferase open reading frame contained in the
psiCheck-2 vector. The recombinant plasmids were then
transfected in cultured HepG2 cells, and luciferase activity
was measured 48h after transfection. The rationale for
using this assay is that the binding of a given cellular
miRNA to the viral target, transcribed together with the
luciferase coding sequence, will repress reporter protein
production thereby reducing luciferase activity compared
to a control. In these experiments, controls were repre-
sented by psiCheck-2 vectors that did not contain any
HBV sequences or contained inverted sequences.
It should be noted that psiCheck-2 also contains a sec-
ondary Photinus (ﬁreﬂy) luciferase cassette designed to
be an intraplasmid transfection normalization reporter.
Figure 1. A computational analysis of hepatitis B virus (HBV) genome by miRanda (24) yielded seven sites that are potential targets for human
miRNAs. Polymerase ORF (P) comprises nucleotides 2309–1625; the overlapping surface antigen ORF (S) comprises nucleotides 2848–839.
MicroRNAs 125a-5p and 125b are products of different genes but have similar sequences thus targeting related sites. The seed region of
miRNAs is marked in bold. Nucleotide numbering is referred to HBV subtype ayw (GeneBank entry X65257.1).
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luciferase signal can be normalized to the ﬁreﬂy luciferase
signal allowing very accurate measurements of the expres-
sion level of the reporter. Under these experimental con-
ditions, the HBV genomic segment 3037–3065, supposed
to be targeted by hsa-miR-125a-5p, inhibited markedly the
expression of the reporter in HepG2 cells. The activity
registered with the wild-type 3037–3065 HBV segment
was in fact 48% lower than that obtained with the
control plasmid containing the inverted sequence (Figure
2, left panel). The inhibition values obtained with the
other six HBV genomic segments were lower than 15%
and did not reach statistical signiﬁcance (data not
shown). On the other hand, the level of inhibition
obtained with the 3037–3065 target is quite impressive
since the assay method reveals the effect of a single en-
dogenous miRNA on the translation of an abundant
mRNA transcribed from the strong SV40 early
enhancer/promoter of the reporter plasmid. It should
also be noted that miR-32, miR-24 and miR-93,
endowed with antiviral activity toward PFV-1 and VSV
(15,17), were shown to inhibit the expression of the
reporter by a similar extent ( 50%). As a further
control of the effect of hsa-miR-125-5p on the viral
target, three mutations, C3058A, C3060G and G3063A,
were introduced in the reporter plasmid, within the region
of complementarity to the seed region of the miRNA.
When the mutated construct was transfected in HepG2
cells, the reporter activity was found to be signiﬁcantly
higher than that obtained with the wild-type construct
(Figure 2, left panel), providing a strong evidence for a
direct interaction between hsa-miR-125a-5p and the viral
target. It should be noted that hsa-miR-125a-5p is one of
the best-scoring miRNAs predicted to bind to HBV
mRNAs (Figure 1). The reason why the other six
miRNAs identiﬁed by MiRanda were not found to
affect the reporter activity is unknown. One possible ex-
planation is that their target sites may have extensive sec-
ondary structures that prevent miRNA binding.
Otherwise it should be hypothesized that the false-positive
rate of MiRanda is higher than expected.
Hsa-miR-125a-5p has been reported to be expressed in
other hepatic cell lines also, such as HuH-7 and PLC/
PRF/5 (7,16,30,31). Testing was then extended to these
cells, revealing similar or slightly higher levels of silencing
activity (Figure 2, center and right panels). It should be
noted that the expression level of the reporter gene in these
cell lines is lower than that registered in HepG2 cells, re-
vealing a different activity of the SV40 early enhancer/
promoter in these cells. Overall, these data indicate that
the 3037–3065 segment HBV genome is sensitive, at the
mRNA level, to the silencing effect of hsa-miR-125a-5p
expressed in hepatic cells.
Silencing activity of hsa-miR-125a-5p
Little is known about the cellular targets of
hsa-miR-125a-5p. This miRNA has been reported to
down-regulate the expression of ERBB2 and ERBB3
oncogenes in cultured breast cancer cells (32) and to
inhibit the expression of p53 gene (33). In both reports,
the interaction of the miRNA with its target was validated
by a luciferase reporter assay yielding levels of inhibition
of gene expression  40%, even if testing was performed
with high miRNA concentrations, either produced by an
exogenous expression cassette or by transfection of a syn-
thetic miRNA mimic.
The anti-HBV activity of hsa-miR-125a-5p was then
inquired by the use of a synthetic miRNA-mimic and an
antisense inhibitor. Transfection of hsa-miR-125a-5p
mimic in HepG2 cells increased the reporter-silencing
effect of the endogenous miRNAs to 69% (Figure 3A).
An antisense miRNA inhibitor was then used to
knockdown the endogenous hsa-miR-125a-5p. When the
inhibitor was transfected in HepG2 cells, the
reporter-silencing activity of the endogenous miRNAs
was signiﬁcantly reduced (Figure 3B). These data clearly
indicate that the silencing effect of cellular miRNAs
toward the HBV genomic segment 3037–3065 can be
attributed to hsa-miR-125a-5p.
At this stage of the work we became aware of some
interesting results from a study on miRNA expression
proﬁles in cultured hepatic cells. By using a miRNA
Figure 2. Interfering activity of hsa-miR-125a-5p in cultured hepatic cells. HepG2, HuH-7 and PLC/PRF/5 cells were transfected with the
luciferase-based reporter plasmid psiCheck-2 containing the HBV 3037–3065 genomic segment belonging to the polymerase/surface antigen ORF
(WT). Other plasmids contained a control DNA with inverted sequence (I), or a mutated viral sequence (M) characterized by 3nt substitutions
(C3058A, C3060G and G3063A) in the region of complementarity to the seed region of the miRNA. Luciferase activity was recorded 48h after
transfection. Luciferase activities registered with the wild-type viral DNA (WT) were always lower than those observed with the control DNA with
inverted sequence (I), indicating that the endogenous hsa-miR-125a-5p can interact with the viral sequence. P-values at Student’s t-test were
*P<0.05, **P<0.01 or ***P<0.001. Rr-luc, Renilla reniformis luciferase; Pp-luc, Photinus pyralis (ﬁreﬂy) luciferase.
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that 11 miRNAs, including hsa-miR-125a-5p are
expressed in the HBV-producing cell line HepG2.2.15 at
levels at least 3-fold higher than in its parent cell
line HepG2 (31). These results raise the possibility that
the expression of hsa-miR125a-5p is inducible and
correlated to the viral infection. In this regard, it has
very recently reported that the expression in HepG2 cells
of HBV X protein increases the expression level of
hsa-miR125a-5p (34).
Effect of hsa-miR-125a-5p on viral translation
The assays described above are based on the silencing
effect of hsa-miR-125a-5p on the translation of a
chimeric mRNA containing the Renilla luciferase coding
sequence and a segment of HBV mRNA. The data col-
lected clearly indicated that hsa-miR-125a-5p is able,
at physiological concentration, to interact effectively
with the viral sequence thereby silencing the luciferase ex-
pression. However, it was not known whether the same
miRNA could be able to interfere with the translation of
the natural HBV mRNAs. This point was then addressed
by the use of the human hepatoma cell line PLC/PRF/5
that contains several copies of HBV DNA integrated in its
genome. This cell line does not produce infectious HBV
particles but expresses the HBV S gene into the mature
hepatitis B surface antigen (HBsAg) in 22-nm spherical
particles that are secreted in the culture medium (35). In
this system, cells were transfected with the synthetic
hsa-miR-125a-5p mimic and the effect on viral translation
of the surface antigen mRNA was assessed by a diagnostic
ELISA assay for HBsAg. Transfection of the mimic
induced a 46% decrease of the expression of HBsAg
(Figure 4A). This level of inhibition is remarkable if we
consider that there is a background level of uninhibited
translation due to preexisting expression of the endogen-
ous target gene and to the fact that the exogenous
miRNA-mimic is not expected to transfect all cells. In a
control experiment, transfection of the mimic was found
to increase the average cellular content of hsa-miR-
125a-5p by  3-fold. RT–PCR was then used to quantitate
the surface antigen mRNA in PLC/PRF/5 cells trans-
fected with the hsa-miR-125a-5p mimic or with the
control miRNA. This assay indicated that hsa-miR-
125a-5p does not affect the concentration of the target
mRNA, revealing that its silencing effect is due to trans-
lation inhibition rather than mRNA cleavage.
Overall, these results clearly indicate that hsa-miR-125a
is able to interfere with the viral translation of surface
antigen mRNAs, thus reducing the amount of HBsAg.
In a ﬁnal experiment, the synthetic miRNA inhibitor
was transfected into the PLC/PRF/5 cells to knock-down
hsa-miR-125a-5p. This induced a signiﬁcant increase in
Figure 3. The silencing effect of hsa-miR-125a-5p in HepG2 cells can
be modulated by a synthetic miRNA mimic (A) or inhibitor (B). Cells
were transfected with the reporter plasmid psiCheck-2 containing the
wild-type HBV fragment (WT) or a control DNA with inverted
sequence (I), along with 10nM hsa-miR-125a-5p mimic (miR-125a,
A) or 50nM hsa-miR-125a-5p inhibitor (anti-miR-125a, B). Further
controls were a miRNA mimic (Ctrl-miRNA) or inhibitor
(Ctrl-anti-miRNA) with unrelated sequences. Luciferase activity was
recorded 48h after transfection. P-values are indicated as described in
Figure 2.
Figure 4. Hsa-miR-125a-5p interferes with viral expression of surface
antigen. PLC/PRF/5 cells were transfected with 10nM hsa-miR-
125a-5p mimic (miR-125a, A) or 50nM hsa-miR-125a-5p inhibitor
(anti-miR-125a, panel B). Controls were miRNA mimic (Ctrl-
miRNA) or inhibitor (Ctrl-anti-miRNA) with unrelated sequences.
Forty-eight hours after transfection HBsAg was quantitated by an
ELISA test. P-values are indicated as described in Figure 2.
Nucleic Acids Research, 2011,Vol.39, No. 12 5161the expression of HBsAg (Figure 4B), providing a direct
evidence that the interaction between the selected miRNA
and the viral mRNA occurs naturally in PLC/PRF/5 cells,
leading to a reduced expression of HBsAg.
The HBV 3037–3065 genomic segment, targeted by
hsa-miR-125a-5p, encodes amino acid residues 244–252
of polymerase and 64–72 of surface antigen. The active
site of HBV polymerase has not been fully characterized
since a three-dimensional structure of the enzyme has not
been determined yet. Based on its primary structure and
mutational studies (36), the encoded amino acids fall
within a polymerase region, the spacer (residues 178–
336) that is far from the YMDD catalytic motif.
However, it cannot be ruled out the possibility that the
encoded residues contribute to the folding and function-
ality of the enzyme. In this regard, it has been reported a
lamivudine-resistant HBV variant showing an amino acid
substitution in the spacer region (37). On the other hand,
the encoded residues of the surface antigen fall within the
extracellular pre-S1 domain of the protein that is respon-
sible for receptor binding on hepatocytes. Furthermore,
they overlap to an amino acid segment (residues 1–75)
that has been shown to be essential for infectivity (38).
This may pose constrains for the virus not to mutate
this region. In this regard, we performed a BLAST
search of nucleotide databases looking for sequences hom-
ologous to the HBV 3037–3065 genomic segment. This
search yielded over 4000 entries identical to the query
sequence and belonging to HBV strains and/or isolates
of all subtypes (ayw, adw, adr, ayr and adyw). This
ﬁnding conﬁrms that the HBV target site for binding of
hsa-miR-125a-5p is very well conserved.
CONCLUSIONS
Human HBV infection has a wide range of clinical
outcomes, from self-limited asymptomatic infection to ful-
minant hepatitis and death (23,39). In addition, chronic
infection is closely correlated with the development of
hepatocellular carcinoma (40). Although new infections
are preventable through vaccination, new antiviral
agents are being sought for the treatment of the over
300-million affected individuals worldwide (41). This
work shows that hsa-miR-125a-5p, a microRNA ex-
pressed in human liver, is able to down-regulate the ex-
pression of HBV S gene thus reducing the amount of
secreted HBsAg. This effect will likely counteract viral
replication, since it is known that (i) the expression
levels of HBsAg are correlated with viral titer, and (ii) ex-
perimental knockdown of HBsAg leads to suppression of
HBV replication (42). If these observations are conﬁrmed
by experiments in vivo, then it is possible to hypothesize
that the mild outcome of HBV infection observed in many
individuals is not only due to the well-known immune
response but also to an RNA-mediated defense operated
by hepatic cells. In this scenario, delivery of synthetic
hsa-miR-125a-5p mimics or treatments that modulate
the expression of cellular hsa-miR-125a-5p could repre-
sent useful strategies in developing new anti-HBV thera-
peutics. Finally, the determination of the expression levels
of hsa-miR-125a-5p in different individuals may also be
useful in studying susceptibility to infection.
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